1. J.W. Valle, et al. 68O - Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cance...
1.Oh DY, He AR, Qin S, et al. Three-year survival, safety and extended long-term survivor analysis from the phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer. Ann Oncol. 2024;35(suppl 1):S117. doi:10.1016/j.annonc.2024.05.285 2.Oh DY, Ruth He A, Qin...
7. Kohei Nakachi, et al. Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group, A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan ...
4. Takuji Okusaka, et al. 93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study. ESMO Asia Congress 2022. Annals of Oncology (2022) 33 (suppl_9): S1454-S1484. 10.1...
1. Toyoda H, et al. Improved survival of viral hepatocellular carcinoma but not non-viral hepatocellular carcinoma from 2000 to 2020: A multi-centre cohort study of 6007 patients from high-volume academic centres in Japan. Aliment Pharmacol Ther. 2022; 56: 694– 701. ...
Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.21531 Background: At the primary analysis of TOPAZ-1 (NCT03875235; data cut-off [DCO] Aug 11, 2021), durvalumab (D) + gemcitabine and ...
2. Do-Youn Oh, et al. 78P - Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). ESMO Asia Congress 2022. Annals of Oncology (2022) 33...
我们要坚持走___，建设中国特色社会主义法治体系、建设社会主义法治国家，围绕保障和促进社会公平正义，坚持依法治国、依法执政、依法行政共同推进，坚持法治国家、法治政府、法治社会一体建设，全面推进科学立法、严格执法、公正司法、全民守法，全面推进国家各方面工作法治化。()
The historical study on which the gemcitabine-cisplatin regimen was based was the ABC-02 trial. In that trial, patients were treated for 6 months with chemotherapy and then followed. In some parts of the world, that’s the standard. In the United States, oftentimes we treat as long as ...
⑤The Lancet Oncology:BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study 首创EGFR/HER3的ADC创新生物药BL-B01D1单药用于局部晚期或转移性实体瘤患者的...